Halozyme Therapeutics, Inc. Insider Selling: Helen Torley Trims Stake

A Form 4 filed with the SEC shows Helen Torley, Pres, CEO at Halozyme Therapeutics, Inc. (HALO), sold 60,000 shares of company stock on 2026-10-06.

The transaction was executed at a price of $110.18 per share, for a total value of approximately $6.61 million.

Under SEC rules, corporate insiders — officers, directors, and holders of more than 10% of a company's shares — are required to report changes in their ownership within two business days of the transaction via Form 4.

Insider sales are common and can occur for reasons unrelated to a company's outlook, including scheduled trading plans, diversification, or personal financial planning.